Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING LLC

Companion Diagnostic to Help Development of Cancer Therapy

By Labmedica International staff writers
Posted on 14 Mar 2012
A companion diagnostic test is to be created to aid in the development of an investigational cancer therapy.

Abbott (Abbott Park, Il, USA) will collaborate with Merck (Whitehouse Station, NJ, USA) to evaluate the use of a fluorescence in situ hybridization (FISH)-based companion diagnostic test to aid in the development of a Merck investigational cancer therapy.

FISH-based companion diagnostic tests are designed to identify specific DNA sequences to help determine which patients are likely to benefit from a particular therapy. FISH technology can identify whether too many, or too few, copies of a particular gene are present in the body's cells, or whether certain genes have rearrangements that play an active role in disease progression. Cancer diagnostics is one of its fastest growing applications.

Abbott will develop a test based on its FISH technology, intended to identify deletions of the TP53 gene in cancer patients. The Abbott FISH assay will be evaluated in clinical trials to help identify patients more likely to respond favorably to Merck’s investigational cancer therapy.

Abbott Molecular is a leader in molecular diagnostics. The company analyses DNA and RNA at the molecular level. "Our goal through this collaboration, and others like it, is to ensure that the right medicine gets to the right patient," said Stafford O’Kelly, head of Abbott’s molecular diagnostics business. "As one of the early pioneers in companion diagnostics, we believe that linking genetic testing with drug development at the earliest stages can increase the effectiveness and predictability of medicines and help physicians make more informed treatment decisions."

Abbott's portfolio of companion diagnostic tests includes the PathVysion HER-2 DNA probe kit, which represents one of the first examples of innovations in the field of personalized medicine. The test is approved for use in selecting breast cancer patients for whom Herceptin (trastuzumab) therapy is being considered. In addition, Abbott's Vysis ALK Break Apart FISH probe kit was approved in 2011 for use in identifying non-small-cell lung cancer patients for Xalkori (crizotinib) treatment.

Related Links:

Abbott
Merck


KARL HECHT GMBH & CO KG
MEDLAB Asia
CELLAVISION AB
PERIPHERAL VISIONS INC

Channels

Hematology

view channel

PROPPR Trial Supports Use of Transfusion Protocol Initially Developed for Battlefield Trauma Patients

In a groundbreaking multisite prospective clinical trial, the damage control resuscitation (DCR) protocol for massive blood transfusion significantly improved severe trauma patient outcome from hemorrhagic shock, when compared to another commonly used protocol. DCR, used in most hospitals today, was first developed by... Read more

Lab Tech.

view channel
Image:  The Flame – a miniature spectrometer for medical diagnostics, biotechnology, and life sciences, that brings flexible optical sensing power to laboratory and point-of-care instrument integration (Photo courtesy of Ocean Optics).

Next Generation Miniature Spectrometer Brings Flexibility to Diagnostics and Biotechnology

The mini spectrometer combines decades of pioneering miniature spectrometer design expertise with leading techniques, adding flexible optical sensing power to laboratory and point-of-care instrument integration.... Read more

Industry News

view channel

Healthcare Revolution Predicted with Rise of Genomic Testing for Personalized Medicine

A new Frost & Sullivan (Mountain View, CA, USA) analysis has found that the direct-to-individual sector of genomic testing is now thriving, though not without criticism about the potential medical interpretation of some forms of tests that may have been initially requested for nonmedical purposes, such as those for... Read more
 

Events

08 Mar 2015 - 12 Mar 2015
18 Mar 2015 - 20 Mar 2015
18 Mar 2015 - 18 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.